Previous 10 | Next 10 |
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Andrew Partridge as executive vice president and chief co...
Deals and Financings Ocumension [HK:1477], a Shanghai ophthalmic pharma, completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion (see story ). Founded in 2017, Ocumension was incubated by 6 Dimensions Capital...
Turning Point Therapeutics (NASDAQ: TPTX) on Tuesday licensed Greater China rights to its tyrosine kinase inhibitor, repotrectinib, to Zai Lab (NASDAQ: ZLAB) for $25 million in cash up front, plus up to $151 million in development, regulatory and sales milestones, and tiered mid-to...
Turning Point Therapeutics ( TPTX +0.6% ) signs an agreement with Zai Lab ( ZLAB +4.3% ) for Turning Point’s lead drug candidate, repotrectinib for lung cancer. More news on: Turning Point Therapeutics, Inc., Zai Lab Limited, Healthcare stocks news, Read more ...
Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China Turning Point to Receive $25 Million Upfront, Potential for Future Milestones of up to $151 Million and Royalties TRIDENT-1 Phase 2 Registrational Study of Repotrectinib to Open Addit...
Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China Turning Point to Receive $25 Million Upfront, Potential for Future Milestones of up to $151 Million and Royalties TRIDENT-1 Phase 2 Registrational Study of Repotrectinib to Open Addit...
Turning Point Therapeutics ( TPTX +1.9% ) announces encouraging results from preclinical studies evaluating lead drug repotrectinib, a tyrosine kinase inhibitor. Results showed that the combination of repotrectinib and proxy molecules for Amgen's AMG510 or Novartis' Mekinist (trametinib)...
SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today presented preclinical studies highlighting the potential for its lead drug candidate, ...
SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate via webc...
Over the past week, the S&P 500 rose again by 2.75%, almost recovering from its YTD losses. With economies restarting, novel optimism about vaccines and better-than-feared job losses last week, the stock market is behaving very optimistically. Of course, the biggest reason for this strong ...
News, Short Squeeze, Breakout and More Instantly...
Turning Point Therapeutics Inc. Company Name:
TPTX Stock Symbol:
NYSE Market:
Turning Point Therapeutics Inc. Website:
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and the recei...
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET...
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedback from the U.S. Food and Drug Administ...